President
Shilpa Pharma Lifesciences Limited
Doylestown, Pennsylvania, United States
Harshawardhan Bal (Harsh) heads US operations for Shilpa Pharma, Inc., a fully integrated CDMO innovation partner covering DS and DP development and cGMP manufacturing for small molecules and large molecules with facilities accredited by USFDA, Health Canada, EMA, PMDA, KFDA, Cofepris, TGA, and others. Harsh brings global diversified and cross value chain experience in the pharma, biotech and healthcare industry. He has held lead positions at Astellas Pharma, Takeda Oncology and Dana-Farber/Harvard Cancer Center, where he applied bioinformatics and functional genomics for discovery R&D across the immuno-oncology, infectious disease, cardiovascular and metabolic therapy areas. Harsh holds a Ph.D. in Molecular Biology from the National Institute of Immunology, New Delhi where he designed recombinant antibody-based constructs for targeted therapies. He is a graduate of the Executive General Management Program of the UPenn – Wharton School and has authored several peer-reviewed articles as well as books on biomedical informatics by Tata McGraw-Hill and Springer.
Disclosure information not submitted.
Tuesday, April 25, 2023
3:00 PM – 3:15 PM ET